While bile acids (BAs) show promise in modulating depression via TGR5/FXR pathways, key gaps remain in understanding their precise neuroactive mechanisms, human-specific effects, and clinical applicability. The gene discussed is GPBAR1; the disease is depressive symptom measurement.